Sinnvoller Einsatz der GLP-1-Analoga – Medikamentöse Therapie des Typ-2-Diabetes

GLP-1-Rezeptoragonisten stellen eine wichtige injektabile Therapieoption bei Typ-2-Diabetes dar. Sie senken nicht nur Glykämieparameter ohne wesentliches eigenes Hypoglykämierisiko, sondern erlauben auch eine Körpergewichtsabnahme und führen zu einer leichten Senkung des systolischen Blutdrucks. Aufgrund dieser positiven Eigenschaften wurden unterschiedlich lang wirkende GLP-1-Rezeptoragonisten zur zweimal täglichen Injektion, zur einmal täglichen Injektion und zur einmal wöchentlichen subkutanen Injektion eingeführt. Dieser Artikel gibt eine Übersicht über die verschiedenen GLP-1-Rezeptorenagonisten und deren Einsatzmöglichkeiten zur Therapie des Typ-2-Diabetes nach modernen Leitlinien.

GLP-1 receptor agonists (GLP-1RA) are an important therapeutic option for an injectable therapy for type 2 diabetes. GLP-1RA do not only lower glycaemic parameters with a very low own risk of hypoglycaemia, but also allow body weight loss and a reduction of systolic blood pressure. Due to their favorable therapeutic profile different GLP-1RA with short and long duration for twice daily, once daily or once weekly subcutaneous injection were developed. This article gives an overview on the different GLP-RA and their use in the differential therapy of type 2 diabetes according to modern guidelines.

Key words

Type 2 diabetes - therapy - GLP-1 receptor agonists - incretin

• Literatur

• 1 Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists. Lancet 2006; 368: 1696-1705
• 2 Madsbad S, Kielgast U, Asmar M et al. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. Diabetes Obes Metab 2011; 13: 394-407
• 3 Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742
• 4 McCormack PL. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. Drugs 2014; 74: 325-351
• 5 Gallwitz B, Guzman J Dotta et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012; 379: 2270-2278
• 6 Mann KV, Raskin P. Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes. Diabetes Metab Syndr Obes 2014; 7: 229-239
• 7 Fineman MS, Mace KF, Diamant M et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546-554
• 8 Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab 2015; 6: 19-28
• 9 Clements JN, Shealy KM. Liraglutide: an injectable option for the management of obesity. Ann Pharmacother 2015; 49: 938-944
• 10 Thompson AM, Trujillo JM. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes. Ann Pharmacother 2015; 9: 351-359
• 11 Kumar A. Insulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy. Expert Opin Biol Ther 2014; 14: 869-878
• 12 Seufert J, Gallwitz B. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes Metab 2014; 16: 673-688
• 13 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38: 140-149